Cannabinoids have established themselves as therapeutic options in the treatment of pain in recent years. Nevertheless, patients can experience problems when using them, particularly with regard to tolerance. A new aqueous nanodispersion appears to be able to eliminate these problems.
Autoren
- Jens Dehn
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- Early rheumatoid arthritis
C1M has potential as a biomarker
- Osteoporosis
Risk-stratified therapy with osteoanabolic agents improves outcomes
- "Swiss Health Care Atlas"
New indicator: medication for weight regulation
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Treatment of pancreatitis: current study data
How can the risk-benefit profile be improved?
- Prurigo and PN
Anti-inflammatory antipruritic therapy improves quality of life
- Pathophysiology, clinical significance and therapeutic consequences
Eosinophils in asthma
- Urothelial carcinoma